tuesday @ medica 10 universal stand “riviera” fully motorized easy and fast positioning new integrated dr system dicom connectivity welcome to our booth hall 10 f 74 contact us by email: sales@primaxint.com t +44(0)1792797910 e marketing@dtrmedical.com www.dtrmedical.com sterilesingle-usedilators and probes thedifference isclear new including, punctum seeker, punctum dilator and lacrimal probes eh @ medica no 2 2016 the association of biofilms with multi-drug resistance has highlighted the need for further understanding of biofilms and for anti-biofilm strate- gies. this september, in a satellite symposium sponsored by heraeus medical, manufacturer of products for orthopaedic surgery and trau- matology, at the 35th annual meet- ing of the european bone and joint infection society, in oxford, the lat- est knowledge of biofilms and local methods of overcoming the chal- lenge of infection was discussed. biofilm-related implant malfunction in orthopaedics, bacteria may colo- nise a surface for months or years but remain undetected until they trig- ger an immune response and signs of infection. during this time, there may be low-grade infection, and symptoms such as persistent pain, stiffness, lack of range-of-movement, fibrosis, ‘aseptic’ implant loosening and non-union of fractures. biofilms and multi-drug resistance a mature biofilm can form within 24 hours of contact with an implant and can even penetrate the surface of titanium. as the biofilm matrix is more abundant than the bacteria themselves, the biofilm must be dis- rupted in order to expose the bacteria to antimicrobial agents. multi-drug resistance may also be related to biofilm formation, for example, methicillin-resistant staphylococcus aureus (mrsa) pro- duces more biofilm than methicillin- susceptible s. aureus (mssa), and therefore biofilms may magnify the cost, suffering and mortality associ- ated with antibiotic resistance. superior outcome in hip and knee arthroplasty in addition to the well-documented benefit of bone cements such as palacos r+g in total hip replacement (thr), registry data was presented showing that significantly fewer revi- sions are required when that bone cement was used in total knee replacement surgery, compared to all other bone cements (data on file. national joint registry (njr, www. njrcentre.org.uk) data licensed to heraeus medical gmbh, wehrheim). palacos r+g with gentamicin also sig- nificantly outperforms plain palacos. significant reduction of surgical site infections (ssis) it is particularly important to optimise strategies for reducing peri-prosthet- ic joint infections (pjis) in high risk patients, but which bone cement best overcomes the current challenges in pji prevention? a quasi-randomised, double blind study was carried out, comparing the two bone cements, palacos r+g and copal g+c, in patients requiring haemiarthroplasty for a fractured neck of femur. there was a significant reduction in both deep and superficial ssis with copal g+c compared with palacos r+g (tyas b, marsh m, molyneux c. et al. abstract 59 presented at the oxford meeting) explained by the previously- observed high antibiotic concentra- tions in wound fluid. extrapolating the reduction in infection rates to the entire uk hip haemiarthroplasty population would lead to healthcare savings of over £4 million. dual antibiotic-loaded cement does not affect antibiotic resistance pro- files a concern regarding the use of antibi- otic loaded bone cements is whether they cause antibiotic resistance. the study reported no significant differ- ences in resistance between palacos r+g and copal g+c. the only cases of resistance with copal g+c were to gentamicin and clindamycin, which is as expected. resistance to other standard anti- biotics remained low. furthermore, copal g+c completely eradicated infection caused by corynebacterium species and s. aureus. www.heraeus-medical.com over in hall 16, pelican feminine healthcare, a leading uk manufac- turer of single-use medical devices for women’s health, is demonstrating the fetofit, a strapless foetal moni- toring solution and pelispec pro- wall, a vaginal speculum designed to offer added vaginal wall support. ‘simple, secure and strapless, the fetofit is a disposable device specifi- cally designed to secure toco and ctg transducers quickly and eas- ily for foetal monitoring,’ the firm explains. ‘both products offer cost effective but high quality, single-use solutions. developed in conjunction with specialist clinicians, pelican’s market-leading innovations are manufactured to the highest qual- ity standards. this is reinforced by stringent monitoring processes, with over 15,000 quality control checks performed annually and across our product range.’ export manager, michael denver, commented the firm’s single-use products are becoming the choice for health services and professionals worldwide. ‘we are keen to build on this success, especially in latin america, and medica is the perfect platform to appoint new partners and develop existing relationships.’ details: www.pelicanfh.co.uk heraeus medical: understanding biofilms anti-biofilm strategies strapless vaginal w among all cement brands in the njr palacos r+g is superior pelican feminine hall 16 / stand f4 » editor-in-chief: brenda marsh art director: olaf skrober managing editor: sylvia schulz editorial team: sascha keutel, marcel rasch senior writer: john brosky executive director: daniela zimmermann founded by heinz-jürgen witzke correspondents austria: walter depner, michael kraßnitzer, christian pruszinsky. china: nat whitney france: annick chapoy, jane macdougall.germany: anja behringer, annette bus, cornelia wels-maug, holger zorn. great britain: brenda marsh, mark nicholls. malta: moira mizzi. poland: pjotr szoblik. russia: olga ostrovskaya, alla astachova. spain: mélisande rouger, eduardo de la sota. the netherlands: madeleine van de wouw. usa: cynthia e. keen, i.t. communications, lisa chamoff. subscriptions liane kaiser, european hospital, theodor-althoff-str. 45, 45133 essen, germany subscription rate 6 issues: 42 euro, single copy: 7 euro. send order and cheque to: european hospital subscription dept printed by: margreff, essen, germany publication frequency: bi-monthly european hospital issn 0942-9085 representatives china & hongkong: gavin hua, sun china media co, ltd. phone: +86-0755-81 324 036 e-mail: gh@european-hospital.com germany, austria, switzerland: ralf mateblowski phone: +49 6735 912 993, e-mail: rm@european-hospital.com france, italy, spain: eric jund phone: +33 493 58 77 43, e-mail: ej@european-hospital.com gb, scandinavia, benelux: simon kramer phone/fax: +31 180 6200 20 e-mail: sk@european-hospital.com israel: hannah wizer, international media dep. of el-ron adv. & pr co., ltd., phone: +972-3-6 955 367 e-mail: hw@european-hospital.com south korea: ch park, mci phone: +82 2 730 1234, e-mail: chp@european-hospital.com usa & canada: hanna politis, media international tel: +1 301 869 66 10, e-mail: hp@european-hospital.com all company, brand and product names in this publication are the prop- erty of their respective holders. users must obtain permission from those holders before copying or using the owner’s trademarks, product and company names or logos. eh @ medica no 22016 co, ltd. phone: +86-0755-81324036 phone: +496735912993, phone: +33493587743, phone/fax: +31180620020 955367 phone: +8227301234, tel: +13018696610,